Zydus Lifesciences Limited has informed the Exchange about General Updates
ZYDUSLIFE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Zydus Lifesciences has incorporated a wholly owned subsidiary named Zydus MedTech (France) SAS on April 10, 2025, through its existing wholly owned subsidiary Zydus MedTech Private Limited. This new French entity has been set up specifically to acquire equity shares of Amplitude Surgical SA, the French target company. The acquisition was originally announced on March 11, 2025, for an 85.6% stake at Euro 6.25 per share, totalling Euro 256.8 million, with a planned mandatory cash tender offer for the remaining shares and a potential squeeze-out and delisting. The newly incorporated entity has a paid-up capital of just Euro 100 and has not yet commenced business operations, as it has been set up purely as an investment vehicle for the deal.
This is a procedural/structural step that facilitates the previously announced acquisition of Amplitude Surgical, helping with regulatory and tax efficiency in France. It signals continued progress toward closing the deal but does not change the deal economics; shareholders should watch for completion of the block acquisition and the subsequent tender offer.